Orlistat, the only FDA-approved pancreatic lipase (PL) inhibitor for long-term use, has been widely used as an anti-obesity drug in the U.S. and Europe for over a decade. The gene discussed is PNLIP; the disease is obesity due to melanocortin 4 receptor deficiency.